| | |
Per Share
|
| |
Total
|
| ||||||
Public Offering Price
|
| | | $ | 9.50 | | | | | $ | 50,000,001.00 | | |
Underwriting Discounts and Commissions(1)
|
| | | $ | 0.57 | | | | | $ | 3,000,000.06 | | |
Proceeds to us, before expenses
|
| | | $ | 8.93 | | | | | $ | 47,000,000.94 | | |
|
Cowen
|
| |
SVB Leerink
|
|
| | | | | S-1 | | | |
| | | | | S-2 | | | |
| | | | | S-2 | | | |
| | | | | S-3 | | | |
| | | | | S-7 | | | |
| | | | | S-9 | | | |
| | | | | S-13 | | | |
| | | | | S-14 | | | |
| | | | | S-15 | | | |
| | | | | S-16 | | | |
| | | | | S-17 | | | |
| | | | | S-20 | | | |
| | | | | S-26 | | | |
| | | | | S-26 | | | |
| | | | | S-26 | | | |
| | | | | S-27 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 10 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 32 | | | |
| | | | | 35 | | | |
| | | | | 38 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 41 | | |
|
Public offering price per share
|
| | | | | | | | | $ | 9.50 | | |
|
Net tangible book value per share as March 31, 2020
|
| | | $ | 0.49 | | | | | | | | |
|
Increase in net tangible book value per share attributable to the offering
|
| | | | 1.07 | | | | | | | | |
|
As adjusted net tangible book value per share after giving effect to this offering
|
| | | | | | | | | | 1.56 | | |
|
Dilution per share to new investors participating in the offering
|
| | | | | | | | | $ | 7.94 | | |
| | |
As of March 31, 2020 (unaudited)
|
| |||||||||
| | |
Actual
|
| |
Adjusted
|
| ||||||
| | |
(in thousands, except share and per share data)
|
| |||||||||
Cash and cash equivalents
|
| | | $ | 26,389 | | | | | $ | 73,139 | | |
Long-term debt
|
| | | $ | 15,088 | | | | | $ | 15,088 | | |
Stockholders’ equity | | | | | | | | | | | | | |
Common stock: $0.001 par value; 100,000,000 shares
authorized, 36,130,355 shares issued and outstanding, actual; and 41,393,513 shares issued and outstanding, as adjusted |
| | | | 36 | | | | | | 41 | | |
Preferred stock: $0.001 par value; 5,000,000 shares authorized, -0- shares issued and outstanding
|
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 212,384 | | | | | | 259,129 | | |
Accumulated other comprehensive income
|
| | | | 1,136 | | | | | | 1,136 | | |
Accumulated deficit
|
| | | | (192,242) | | | | | | (192,242) | | |
Total Stockholders’ Equity
|
| | | $ | 21,314 | | | | | $ | 68,064 | | |
Total Capitalization
|
| | | $ | 36,402 | | | | | $ | 83,152 | | |
Underwriter
|
| |
Number of Shares
|
| |||
Cowen and Company, LLC
|
| | | | 2,500,000 | | |
SVB Leerink LLC
|
| | | | 2,236,842 | | |
B. Riley FBR, Inc.
|
| | | | 526,316 | | |
Total
|
| | | | 5,263,158 | | |
| | | | | | | | |
Total
|
| |||||||||
| | |
Per Share
|
| |
Without
Option |
| |
With
Option |
| |||||||||
Public offering price
|
| | | $ | 9.50 | | | | | $ | 50,000,001.00 | | | | | $ | 57,499,994.50 | | |
Underwriting discount
|
| | | $ | 0.57 | | | | | $ | 3,000,000.06 | | | | | $ | 3,449,999.67 | | |
Proceeds, before expenses, to CytoSorbents
|
| | | $ | 8.93 | | | | | $ | 47,000,000.94 | | | | | $ | 54,049,994.83 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 10 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 25 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 32 | | | |
| | | | | 35 | | | |
| | | | | 38 | | | |
| | | | | 40 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 41 | | |